MedTrace Logo

Study of Maraviroc (MVC) and Epzicom (ABC/3TC) Once-Daily in ART-Naive & First Switch Patients

NCT02626923 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 51

Last updated 2015-12-10

No results posted yet for this study

Summary

Hypotension does not occur with Maraviroc at a dose of 600 mg/day

Conditions

  • Drug-induced Hypotension

Sponsors & Collaborators

Principal Investigators

  • Nicholaos C Bellos, MD · Southwest Infectious Disease, PA

Eligibility

Min Age
21 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2014-03-31
Completion
2014-03-31

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02626923 on ClinicalTrials.gov